N

New England Retina Consultants | Retina Research Institute

Research site

(Unclaimed)

Location

3640 Main Street Suite 202A, Springfield, Massachusetts, United States of America

Site insights

Top conditions

Top treatments

KSI-301

Tarcocimab

Triamcinolone Acetonide

ADX-2191

methotrexate

APL-2

CU06-1004

AVD-104

ANX007

AXT107

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 14 total trials

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (SIGLEC)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting

Macular Degeneration

Geographic Atrophy of the Macula

Drug: AVD-104

Drug: Avacincaptad

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA) (ARCHER II)

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling

Geographic Atrophy

Drug: ANX007

Other: Sham Administration

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) (GLOW2)

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Enrolling

Non-proliferative Diabetic Retinopathy

Drug: Tarcocimab

Other: Sham injection

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) (DISCOVER)

The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question\[s\] it...

Active, not recruiting

Neovascular Age-related Macular Degeneration

Drug: AXT107 Mid Dose

Drug: AXT107 High Dose